Complement C5 mAb in the Treatment of Anti-GBM Disease

NCT06513338 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

16

Enrollment

OTHER

Sponsor class

Conditions

Autoimmune Diseases

Interventions

DRUG: Eculizumab

Sponsor

Peking University First Hospital